In This Article:
As global markets navigate a landscape of easing inflation and robust bank earnings, U.S. stocks have rebounded, with value stocks outperforming growth shares amid a backdrop of strong financial sector performance. In this environment, identifying growth companies with high insider ownership can be particularly appealing as it often signals management's confidence in their business prospects and aligns their interests with those of shareholders.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 41.2% |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
People & Technology (KOSDAQ:A137400) | 16.4% | 37.3% |
SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
Medley (TSE:4480) | 34.1% | 27.2% |
Plenti Group (ASX:PLT) | 12.7% | 120.1% |
Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 108.3% |
Findi (ASX:FND) | 35.8% | 110.7% |
Here we highlight a subset of our preferred stocks from the screener.
Moltiply Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Moltiply Group S.p.A. operates comparison platforms and offers outsourcing services for credit processes, asset management, and insurance claims management in Italy, with a market cap of €1.34 billion.
Operations: The company generates revenue from its Mavriq Division (€208.81 million) and Moltiply BPO&Tech (€225.83 million) segments.
Insider Ownership: 22.9%
Moltiply Group is poised for significant growth, with earnings expected to increase 29.7% annually, outpacing the Italian market's 6.8%. Revenue growth of 7.4% per year also surpasses the local market average of 4.1%. However, its Return on Equity is forecasted to remain low at 15.1% in three years. Recent discussions about acquiring Verivox GmbH for over €250 million ($263 million) could enhance its strategic position and drive further expansion opportunities.
Beijing Konruns PharmaceuticalLtd
Simply Wall St Growth Rating: ★★★★★☆
Overview: Beijing Konruns Pharmaceutical Co., Ltd. is involved in the research, development, production, and sale of pharmaceuticals both in China and internationally, with a market cap of CN¥3.72 billion.
Operations: The company's revenue is primarily derived from its Pharmaceutical Manufacturing segment, which generated CN¥846.29 million.